Zhejiang Xidamen New Material (605155)
Search documents
机构风向标 | 西大门(605155)2025年三季度已披露持仓机构仅3家
Xin Lang Cai Jing· 2025-10-25 03:05
Core Insights - Xidamen (605155.SH) reported its Q3 2025 results on October 25, 2025, highlighting a total of 3 institutional investors holding shares, amounting to 5.1483 million shares, which represents 2.69% of the total share capital [1] - The institutional holding percentage decreased by 0.60 percentage points compared to the previous quarter [1] Institutional Investors - The institutional investors include Zhejiang Xidamen New Materials Co., Ltd. repurchase special securities account, MORGAN STANLEY & CO. INTERNATIONAL PLC., and UBS AG, collectively holding 2.69% of the shares [1] - There were 45 public funds disclosed this period, including notable funds such as NuAn Duo Strategy Mixed A, Jiao Yin Rui Yuan Three-Year Regular Open Mixed, and Shanghai Composite Index ETF [1] Foreign Investment - Two new foreign institutions disclosed their holdings this quarter, namely MORGAN STANLEY & CO. INTERNATIONAL PLC. and UBS AG [1]
西大门(605155.SH)发布前三季度业绩,归母净利润8793万元,同比增长1.16%
智通财经网· 2025-10-24 14:21
Core Insights - The company reported a revenue of 651 million yuan for the first three quarters of 2025, representing a year-on-year growth of 10.43% [1] - The net profit attributable to shareholders reached 87.93 million yuan, showing a year-on-year increase of 1.16% [1] - The net profit after deducting non-recurring items was 81.15 million yuan, which reflects a year-on-year decline of 4.66% [1] - The basic earnings per share stood at 0.46 yuan [1]
西大门(605155.SH):第三季度净利润3212.64万元,同比增长0.66%
Ge Long Hui A P P· 2025-10-24 11:15
Core Viewpoint - The company reported a slight increase in revenue and net profit for the third quarter, indicating stable performance despite a decline in net profit excluding non-recurring items [1] Financial Performance - The company achieved an operating revenue of 232 million yuan in the third quarter, representing a year-on-year growth of 3.74% [1] - The net profit attributable to shareholders was 32.1264 million yuan, showing a year-on-year increase of 0.66% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 30.2848 million yuan, reflecting a year-on-year decrease of 3.18% [1] - The basic earnings per share were reported at 0.17 yuan [1]
浙江西大门控股股东一致行动人提前终止减持计划 未减持15.7万股股份
Xin Lang Cai Jing· 2025-10-24 09:18
Core Viewpoint - Zhejiang Xidamen New Materials Co., Ltd. announced the early termination of the share reduction plan by its controlling shareholders, indicating no shares were sold during the planned period [1][3]. Group 1: Share Reduction Plan - The initial plan was to reduce up to 157,000 shares, representing 0.0821% of the total share capital, from October 20, 2025, to January 19, 2026 [2]. - The shareholders involved in the plan included Zhang Xiangjuan (35,000 shares, 0.0183%), Liu Xiaohua (102,000 shares, 0.0533%), and Wang Weirong (20,000 shares, 0.0105%) [2]. Group 2: Execution and Termination Reasons - As of the announcement date, no shares were sold, with a total reduction of 0 shares and 0 yuan in total amount [3]. - The reason for the early termination was stated as "based on personal needs," without further details provided [3]. Group 3: Shareholder Structure - Zhang Xiangjuan, Liu Xiaohua, and Wang Weirong are considered concerted actors of the controlling shareholder and actual controller, Liu Qinghua [4]. - Together with another concerted actor, Wang Yuehong, they hold a total of 115.699 million shares, accounting for 60.4810% of the total share capital [4]. Group 4: Impact of the Announcement - The termination of the share reduction plan suggests no immediate liquidity pressure from shareholder reductions in the market [5]. - The company stated that this decision would not significantly impact its governance structure or ongoing operations, maintaining a stable shareholder structure [5].
西大门:前三季度净利润同比增长1.16%
Zheng Quan Shi Bao Wang· 2025-10-24 09:13
Core Insights - The company reported a third-quarter revenue of 232 million yuan, representing a year-on-year increase of 3.74% [1] - The net profit for the third quarter was 32.1264 million yuan, showing a year-on-year growth of 0.66% [1] - For the first three quarters, the total revenue reached 651 million yuan, with a year-on-year increase of 10.43% [1] - The net profit for the first three quarters was 87.9309 million yuan, reflecting a year-on-year growth of 1.16% [1] - The basic earnings per share stood at 0.46 yuan [1]
西大门:10月24日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-10-24 09:13
Group 1 - The core point of the article is that Xidamen (SH 605155) held its fourth board meeting on October 24, 2025, to discuss the management system for senior executives' departure [1] - For the year 2024, Xidamen's revenue composition is as follows: 57.11% from sunshade fabric manufacturing, 39.72% from sunshade finished products manufacturing, 2.02% from other manufacturing, and 1.14% from other businesses [1] - As of the report, Xidamen has a market capitalization of 2.9 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, highlighting a contrast between the hot secondary market and the cold fundraising environment in the primary market for the biopharmaceutical sector [1]
西大门:2025年前三季度净利润约8793万元
Mei Ri Jing Ji Xin Wen· 2025-10-24 09:12
Group 1 - The core viewpoint of the article highlights the financial performance of Xidamen, with a revenue increase of 10.43% year-on-year for the first three quarters of 2025, amounting to approximately 651 million yuan [1] - The net profit attributable to shareholders for the same period is approximately 87.93 million yuan, reflecting a year-on-year increase of 1.16% [1] - As of the report date, Xidamen's market capitalization stands at 2.9 billion yuan [2] Group 2 - The article discusses the broader context of the biopharmaceutical market, noting that Chinese innovative drugs have generated 80 billion USD in overseas licensing this year [2] - It raises questions about the disparity between the hot secondary market and the cooling fundraising environment in the primary market for biopharmaceuticals [2]
西大门(605155) - 控股股东的一致行动人提前终止减持计划暨未减持公司股份的公告
2025-10-24 09:04
证券代码:605155 证券简称:西大门 公告编号:2025-037 浙江西大门新材料股份有限公司 控股股东的一致行动人提前终止减持计划 暨未减持公司股份的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 大股东及董监高持股的基本情况 本次减持计划实施前,浙江西大门新材料股份有限公司(以下简称"公司") 控股股东的一致行动人张香娟女士、柳小华先生、王伟荣先生持有公司 157,000 股,占公司总股本比例为 0.0821%。 减持计划的实施结果情况 2025 年 9 月 19 日,公司发布了《控股股东的一致行动人集中竞价减持股份 计划的公告》(公告编号 2025-035),公司控股股东的一致行动人张香娟女士、 柳小华先生、王伟荣先生计划自 2025 年 10 月 20 日至 2026 年 1 月 19 日通过集 中竞价方式减持不超过 157,000 股,占公司总股本的 0.0821%。 截至本公告披露日,张香娟女士、柳小华先生、王伟荣先生未减持公司股份。 近日,公司收到控股股东的一致行动人张香娟女士 ...
西大门(605155) - 董事、高级管理人员离职管理制度
2025-10-24 09:02
浙江西大门新材料股份有限公司董事、高级管理人员离职管理制度 浙江西大门新材料股份有限公司 董事、高级管理人员离职管理制度 (2025年10月修订) 第一章 总则 第一条 为规范浙江西大门新材料股份有限公司(以下简称"公司")董事、 高级管理人员离职管理,确保公司治理结构的稳定性和连续性,根据《中华人 民共和国公司法》(以下称《公司法》)、《中华人民共和国证券法》(以下 简称《证券法》)、《上市公司治理准则》《上海证券交易所股票上市规则》 等法律法规、规范性文件、证券交易所业务规则及《公司章程》的有关规定, 结合公司实际情况,制定本制度。 第二条 本制度适用于公司全体董事(含独立董事)及高级管理人员的主动 辞职或辞任、任期届满卸任、被解除职务、更换或解聘以及其他导致董事、高 级管理人员实际离职等情形。 第二章 离职情形 第三条 公司董事、高级管理人员可以在任期届满以前辞任。董事、高级管 理人员在任期届满前辞职的,应当向公司提交书面辞职报告,辞职报告中应说 明辞职原因。董事辞任的,自公司收到通知之日起辞任生效。高级管理人员辞 任的,自董事会收到辞职报告时生效。公司将在收到辞职报告后2个交易日内披 露董事、高级管理 ...
西大门(605155) - 信息披露暂缓、豁免管理制度
2025-10-24 09:02
浙江西大门新材料股份有限公司信息披露暂缓、豁免管理制度 浙江西大门新材料股份有限公司信息披露暂缓、豁免管理制度 (2025年10月修订) 第一章 总则 第一条 为规范浙江西大门新材料股份有限公司(以下简称"公司")的信息 披露暂缓与豁免行为,确保公司及相关信息披露义务人依法履行信息披露义务 ,切实保护投资者的合法权益,根据《中华人民共和国证券法》《上海证券交 易所股票上市规则》(以下简称《股票上市规则》)、《上市公司信息披露管 理办法》《上市公司信息披露暂缓与豁免管理规定》《上海证券交易所上市公 司自律监管指引第2号——信息披露事务管理》等相关法律、法规、规范性文件 并结合《公司章程》及公司《信息披露事务管理制度》等有关规定,特制定本 制度。 第二条 公司及相关信息披露义务人暂缓、豁免披露临时报告,在定期报告、 临时报告中豁免披露中国证监会和上海证券交易所规定或者要求披露的内容, 适用本制度。 第三条 公司及相关信息披露义务人应当真实、准确、完整、及时、公平地 披露信息,不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者,不得 实施内幕交易、操纵市场等违法行为。 第四条 公司及相关信息披露义务人应当审慎确定 ...